Deerfield
About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More
---
Investment

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More
---
Information

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---
Philanthropy

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
---
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
---
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
---
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
---
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
---
Cure Campus

Cure is a 12-story innovation campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Frank Nestle, M.D., FMedSci

Frank Nestle, M.D., FMedSci, is a Partner at Deerfield and member of the therapeutics team.  Frank leads Deerfield’s drug discovery and development efforts and applies his expertise to all aspects of our investment process.  Prior to joining Deerfield in 2024, Dr. Nestle was Global Head of Research and Chief Scientific Officer at Sanofi, where he oversaw all research therapeutic areas and platforms.  Before this, Dr. Nestle was Professor and Chair of Cutaneous Medicine and Immunotherapy at King’s College London and practiced medicine at Guy’s and St. Thomas Hospital in London and the University Hospital in Zürich.  Dr. Nestle has also held leadership roles in several academic and professional organizations and served on the board of several private companies. Dr. Nestle holds an M.D. from The Julius Maximilian’s University of Würzburg and is a Fellow of the UK Academy of Medical Sciences.

Hongbin Wan, Ph.D.

Hongbin Wan, Ph.D., is a Senior Scientist, Deerfield Discovery and Development, and joined the Firm in 2024. Prior to Deerfield, Dr. Wan was with Novartis Institutes for BioMedical Research for almost five years, most recently as Senior Expert, Data Science. Dr. Wan holds a Bachelor of Chemical Engineering from the University of Delaware and a Ph.D. in Chemistry from Temple University.

Lin Yan, Ph.D.

Lin Yan, Ph.D. is a Senior Director, Medicinal Chemistry, Deerfield Discovery and Development, and joined the Firm in 2024. Prior to Deerfield, Dr. Yan was a Senior Director, Head of Chemistry for Exarta Therapeutics and Senior Director, Head of Chemistry at Eternity Bioscience, Inc. Prior to these roles, Dr. Yan spent 19 years with Merck Research Laboratories, most recently as a Principal Scientist, and three years with Bristol-Myers Squibb as a Research Investigator II. Dr. Yan holds a B.S. in Chemistry from the University of Science and Technology of China and a Ph.D. in Chemistry from Princeton University.

Xiaodong Lin, Ph.D.

Xiaodong Lin, Ph.D., is a Senior Director, Medicinal Chemistry, Deerfield Discovery and Development, and joined the Firm in 2024. Prior to Deerfield, Dr. Lin was a Director of Medicinal Chemistry at Exelixis for three years. Before Exelixis, she was with Novartis for 15 years most recently as a Medicinal chemist, and with Chiron Corporation for 10 years, most recently as a Senior Scientist. Dr. Lin holds a B.S. in Chemistry from the School of Pharmacy at Peking University and a Ph.D. in Organic Chemistry from the University of Maryland.

Jacob Spiegel, Ph.D.

Jacob Spiegel, Ph.D., is a Senior Scientist, Deerfield Discovery and Development, and joined the Firm in 2024. Prior to Deerfield, Dr. Spiegel was a Cheminformatic Research Engineer at Exscientia AI for two years. Before Exscientia, he was Vice President of Product Development as well as a Research Informatics Consultant at Workflow Informatics Corp. Dr. Spiegel holds a B.E. in Biomedical Engineering from Stony Brook University and a Ph.D. in Molecular Biophysics and Structural Biology with a Ph.D. Minor in Teaching from the University of Pittsburgh. 

Jakob Loschko, Ph.D.

Jakob Loschko, Ph.D., is a Director, Biologics, Deerfield Discovery and Development, and joined the Firm in 2023. Prior to Deerfield, Dr. Loschko spent almost seven years at Pfizer in roles of increasing responsibility, including most recently as Associate Director, Vaccine R&D. Prior to Pfizer, Dr. Loschko spent four years at The Rockefeller University as a Postdoctoral Associate. He holds a Diploma in Biology from the University of Regensburg in Germany and a Ph.D. in Immunology from the Technical University of Munich.

Holly Schachner, M.D.

Holly Schachner, M.D., is the Chief Medical Officer, Deerfield Discovery and Development and joined the Firm in 2023. Prior to Deerfield, Dr. Schachner was the Head of Clinical Development at North Sea Therapeutics, B.V. and she was the Chief Medical Officer at Double Rainbow Biosciences. Before these roles, she was the Senior Vice President, Clinical Development and Therapeutic Area and Innovative Trial Design Head for Myokardia-BMS and the Chief Medical Officer, Global Specialty Medicine for Allergan. Dr. Schachner also spent five years at Sanofi in various roles of increasing leadership, six years at Bayer Diabetes Care as Senior Director, Head of Global Medical Affairs, and five years at Pfizer. Prior to industry, Dr. Schachner received her training in pediatric endocrinology at Mount Sinai and led the Pediatric Diabetes program at Columbia University. She holds a B.A. in Psychology from the University Of Michigan and an M.D. from SUNY at Stony Brook School of Medicine.

Raheleh Hatami, Ph.D.

Raheleh Hatami, Ph.D., is the New York Regional Scientific Collaboration Director, Deerfield Discovery and Development, and joined the Firm in 2023. Prior to Deerfield, Dr. Hatami was a Healthcare Investor at Innovatus Capital Partners. Before Innovatus, she was an Investments Associate at Roivant Sciences, and a Healthcare Associate at RA Capital Management. Dr. Hatami holds a B.A. in Neuroscience & Behavior from Columbia University, and an M.S. in Biomedical Sciences, Microbiology and a Ph.D. in Biomedical Sciences, Cancer Biology from the Icahn School of Medicine at Mount Sinai.

Chiara Vardabasso, Ph.D.

Chiara Vardabasso, Ph.D., is a Principal Scientist, Preclinical Pharmacology, Deerfield Discovery and Development, and joined the Firm in 2023. Prior to Deerfield, Dr. Vardabasso was a Senior Scientist at Gotham Therapeutics for more than four years. Before Gotham, she was an Instructor in the Department of Oncological Sciences at the Icahn School of Medicine at Mount Sinai, where she was previously a Postdoctoral Fellow. Dr. Vardabasso holds a Ph.D. in Molecular Biology from Scuola Normale Superiore, and an M.Sc. and a B.Sc. in Medical Biotechnology from Universita’ degli Studi di Trieste, both in Italy.

Tiago Vieira, Ph.D.

Tiago Vieira, Ph.D., is a Senior Director, Process Chemistry, Deerfield Discovery and Development, and joined the Firm in 2023. Prior to Deerfield, Dr. Vieira spent nearly 15 years at Gilead Sciences in roles of increasing responsibility including most recently as Director, Process Chemistry, Pharmaceutical Development and Manufacturing. Dr. Vieira holds a B.Sc. in Chemistry and a Ph.D. in Synthetic Organic Chemistry from the University of São Paulo in Brazil.